CMI
49
2
VFC
56
6
MSFT
55
2
FE
34
4
KMI
69
8
MCO
67
3
MKC
54
3
INTU
54
2
EXPD
29
2
DHI
36
3
PPL
44
9
A
43
2
TXN
29
4
NKE
36
2
RF
44
10
LUV
45
3
VRSN
59
4
ADT
12
2
CFG
36
12
AON
25
4
CMI
49
2
VFC
56
6
MSFT
55
2
FE
34
4
KMI
69
8
MCO
67
3
MKC
54
3
INTU
54
2
EXPD
29
2
DHI
36
3
PPL
44
9
A
43
2
TXN
29
4
NKE
36
2
RF
44
10
LUV
45
3
VRSN
59
4
ADT
12
2
CFG
36
12
AON
25
4
Financhill
Back

Essilorluxottica 10K Form

Sell
45

ESLOF
Essilorluxottica

Last Price:
$243.90
Seasonality Move:
0.31%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ESLOF News And Ratings

See the #1 stock for the next 7 days that we like better than ESLOF

ESLOF Financial Statistics

Sales & Book Value

Annual Sales: $27.5B
Cash Flow: $0
Price / Cash Flow: 30.23
Annual Sales: $0.00
Price / Book: 2.63

Profitability

Net Income (TTM): $0
Gross Margin: $17.4B
Return on Equity: 0%
Return on Assets: 0%

Essilorluxottica Earnings Forecast

Key Essilorluxottica Financial Ratios

  • The Gross Profit Margin over the past 23 years for ESLOF is 63.19%.
  • The Selling, General & Administrative Expenses for ESLOF have been equal to 47.45% of Gross Profit Margin.
  • The Research & Development expenses have been 2.34% of Revenue.
  • The Interest Expense is 8.65% of Operating Income.
  • The Net Earning history of ESLOF is 9.01% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 17 years.

Essilorluxottica Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: ESLOF
Website: essilorluxottica.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 44.64
Forward P/E Ratio: 0

ESLOF Technical Analysis vs Fundamental Analysis

Sell
45
Essilorluxottica (ESLOF) is a Sell

Is Essilorluxottica a Buy or a Sell?

  • Essilorluxottica stock is rated a Sell
    The current Essilorluxottica [ESLOF] share price is $240.25. The Score for ESLOF is 45, which is 10% below its historic median score of 50, and infers higher risk than normal.